AZD9496

DRUG2 trials

Sponsors

AstraZeneca

Conditions

ER+ HER2- Advanced Breast CancerPostmenopausal Women With ER+ HER2- Primary Breast Cancer

Phase 1

AZD9496 First Time in Patients Ascending Dose Study

CompletedNCT02248090

AstraZenecaER+ HER2- Advanced Breast Cancer

Start: 2014-10-22End: 2019-04-03Updated: 2019-06-24

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

CompletedNCT03236974

AstraZenecaPostmenopausal Women With ER+ HER2- Primary Breast Cancer

Start: 2017-10-05End: 2019-02-12Updated: 2020-02-06

Related Papers

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

Clinical Cancer Research2020-03-3148 citations

Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer

Cancer Research2020-02-152 citations